The Walden Group Research
Advisory Approach
The Walden Group is a strategic healthcare investment banking and M&A advisory firm specializing in mergers, acquisitions, and corporate transactions for the medical technology and healthcare industries. Founded in 1990, the firm operates with a distinctive philosophy centered on the "all-in" approach—deep immersion with clients to understand their business, positioning, and strategic objectives before conducting a discrete, professional sale process.
The firm's thesis is grounded in three core differentiators: (1) deep, 30+ years of healthcare industry knowledge spanning medical devices, diagnostics, pharmaceuticals, biotech, and healthcare IT; (2) a worldwide network of relationships with multi-nationals, mid-level companies, entrepreneurial firms, and private equity funds; and (3) sophisticated transactional expertise from senior-level healthcare executives who understand clinical, regulatory, and operational complexity.
Sector Focus
The Walden Group maintains active practices across the breadth of healthcare technology and services. Primary focus areas include:
Medical Devices: Walden has exceptional depth in ophthalmic surgical instruments (they have closed more ophthalmic deals than any other category in their track record), orthopedic devices, cardiovascular devices, diagnostic imaging, endoscopy, minimally invasive surgery products, wound care technologies, and specialty surgical instruments. Their expertise extends to regulatory compliance (AS9100, ISO standards), manufacturing operations, and supply chain dynamics.
Diagnostics: Including in vitro diagnostics, companion diagnostics, genetic tests, reagents, immunochemistry, diagnostic instruments and equipment, and diagnostic imaging products and software.
Pharmaceuticals: Anti-infectives, cancer therapies, cardiovascular drugs, dermatologicals, drug delivery systems, generics, nutraceuticals, vaccines, and veterinary pharmaceuticals.
Healthcare Information Systems: Billing systems, electronic medical records, hospital information systems, outcome measurement systems, physician practice management systems, and radiology information systems.
Biotechnology: Including biochemical products, biotech instruments, human therapeutics, and diagnostics.
Healthcare Services & Distribution: Clinical laboratories, diagnostic imaging services, managed care, specialty distribution networks, and dental/hospital distribution channels.
Deal Track Record
The Walden Group has completed more than 175 transactions over its 30+ year operating history. Recent notable transactions include:
2025 Deals:
- Hurricane Medical sale to Innovia Medical (July 2025) — exclusive advisor on sale of leading ophthalmic surgical instruments manufacturer to PE-backed global medical device company
2024-2023 Deals:
- RICA Surgical Products sale to Mastel Precision Surgical Instruments (2024) — ophthalmic surgical instruments and sterile processing supplies to Pacific Surgical family
- Total Titanium (TTI) sale to Bausch & Lomb (NYSE:BLCO) — precision ophthalmic surgical instruments manufacturer to major global eye health company
- Katalyst Surgical merger with Carl Zeiss Meditec AG — vitreoretinal ophthalmic surgery technology to world-leading medical technology company
- ASICO sale to Katena Products (April 2021) — ophthalmic surgical instruments (35+ year track record) to worldwide leader in ophthalmic and optometric products
- Argentum Medical acquisition by Shore Capital Partners (2020) — advanced woundcare company with Silverlon antimicrobial technology to prominent PE healthcare investor
- Riverpoint Medical majority recapitalization with Arlington Capital Partners — advanced bioabsorbable sutures and orthopedic implants to operationally-focused PE firm
Earlier Transactions (Representative):
- Endo Optiks sale to BVI/Roundtable Healthcare Partners — minimally invasive ophthalmic diagnostic and surgical systems
- VasSol stroke diagnostics sale to private investor — NOVA non-invasive stroke diagnostic system
- JoviPak Corporation sale to BSN Medical — lymphedema compression products
- Attentus Medical Sales sale to Medical Specialty Distributors (New Mountain Capital portfolio) — compounding/specialty pharmacy distribution
- Millennium Surgical sale to Avalign Technologies (Arlington Capital) — branded surgical instruments for hospitals and surgery centers
- Life Systems sale to STERIS (NYSE:STE) — endoscopic instrument repair and maintenance
- MicroSurgical Technology sale to Halma plc (LSE:HLMA) — specialized ophthalmic surgical devices
- Total Repair Express sale to STERIS — comprehensive surgical instrument repair services
- Visiometrics sale to Halma — ophthalmic diagnostic instruments for vision quality measurement
- IOP Ophthalmics (Arxa5) acquisition by Katena — amniotic membranes and ophthalmic technologies
The firm's transaction pipeline demonstrates consistent sell-side advisory strength, particularly in small-to-mid-market healthcare technology sales ($10M-$250M TEV). The buyer network includes both strategic acquirers (Fortune 500 healthcare companies, multinational medical device firms, European manufacturers) and active PE sponsors (Arlington Capital, Shore Capital, Private equity groups).
Process & Fee Structure
The Walden Group conducts sell-side M&A processes for privately-owned healthcare technology companies. Their process emphasizes:
- Pre-Process Preparation: Detailed company analysis, positioning development, and preparation of investment-grade materials to credibly convey value and differentiation to buyers.
- Discrete Buyer Identification: Walden identifies target acquirers (strategic and PE), culls prospects based on strategic fit and likelihood of interest, and carefully screens to identify optimal counterparties.
- Professional Process Management: Structured data room preparation, management presentation coaching, coordinated buyer engagement, and negotiation facilitation.
- Closing & Integration Support: Continued involvement through final negotiations and closing logistics.
Fee structure: Modified Lehman scale (most common for their client base). Engagement typically includes an upfront retainer credited against the success fee on transaction close.
Buyer Network
Walden has closed transactions with:
Private Equity Firms: Arlington Capital, Shore Capital Partners, New Mountain Capital, Genstar Capital, Audax Group, Inverness Graham Investments, Bain Capital, KKR Industrials
Strategic Acquirers: Bausch & Lomb (NYSE:BLCO), Carl Zeiss Meditec AG, STERIS (NYSE:STE), Halma plc (LSE:HLMA), BSN Medical, Innovia Medical, Inverness Graham-backed companies, major multinational medical device and pharma firms
The network strength reflects deep relationships in the ophthalmic medical device ecosystem (evidenced by the concentration of ophthalmic deals), active PE connectivity, and broad multinational company relationships.
Competitive Positioning
The Walden Group occupies a distinctive niche in healthcare M&A:
- Industry Depth: 30+ years of specialization in healthcare technology and devices (not generalist banking)
- Operational Understanding: Team includes former med-tech executives, plant managers, and clinical professionals who understand manufacturing, regulatory, and clinical nuances
- Relationship-Driven: Highly relational approach focusing on fit and rapport between parties, not transaction volume
- Discrete, Professional Process: Known for thoughtful, careful process management that maximizes valuation and buyer fit
- Research Capability: Produces quarterly Strategic Healthcare M&A Reports with detailed sector analysis and deal tracking (demonstrates market expertise)
- Founder-Centric: Specializes in representing founder/pioneer/owners of private companies, not institutional sellers
Not a Fit If
The firm typically is not engaged for:
- Highly complex financial restructurings or multi-platform divestitures
- Businesses seeking high-volume, rapid-fire bidding processes (Walden favors discrete, carefully-curated processes)
- Fortune 500 or large public company transactions (they focus on smaller, founder-owned enterprises)
- Cross-border deals with complex regulatory requirements beyond their expertise
- Transactions where buyer relationships or process finesse are less important than pure financial optimization
Team
The Walden Group operates as a boutique firm with a lean professional team. Key team members include:
Richard S. Cohen — President and founder. Has led the firm for 25+ years. Orchestrated 200+ merger, acquisition, and corporate alliance transactions. Recognized expert on healthcare industry dynamics, corporate valuation, and complex transaction strategy. Frequently cited in industry publications and serves on healthcare M&A editorial boards.
Adam S. Cohen — Senior Vice President / Chief Development Officer. Northwestern University BA, MBA from Babson College's F.W. Olin Graduate School of Business. Experienced merger & acquisition professional with background at The Walden Group, MMG Advisors (consumer products and retail investment banking), and Mentor Capital (Boston-based private equity). Brings cross-sector M&A perspective combined with healthcare specialization.
Geographic Coverage
Headquartered in Tarrytown, New York. Operates as a virtual firm with relationships across North America, Western Europe, and select international markets. Primary geographic relationships in the United States, with specific strength in ophthalmic and medical device manufacturing hubs (Northeast, Midwest).
Market Positioning
The Walden Group competes against larger bulge-bracket banks (on capability and process) and generalist boutique investment banks (on healthcare specialization). Its competitive advantage lies in the combination of deep healthcare expertise, founder-centric approach, discrete process discipline, and the caliber of transaction expertise brought to bear. The firm is known in the lower middle market for being the preferred advisor for founder-owned medical technology companies seeking a thoughtful, expert M&A process.
Total Transactions
The firm has completed 175+ transactions over its 30-year operating history. This represents consistent deal activity (average 5-6 deals per year) and deep operating expertise in healthcare M&A execution.